Company Zealand Pharma A/S Nasdaq
Equities
ZEAL
US98920Y3045
Biotechnology & Medical Research
Business Summary
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Number of employees: 270
Sales per Business
DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Peptide-based Medicines
100.0
%
| 104 | 100.0 % | 343 | 100.0 % | +229.65% |
Sales per region
DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Germany
85.9
%
| - | - | 294,509 | 85.9 % | - |
Denmark
12.9
%
| 35 | 33.7 % | 44,185 | 12.9 % | +1,26,142.86% |
United States
1.2
%
| 69 | 66.3 % | 4,094 | 1.2 % | +5,833.33% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 01/10/01 | |
Director of Finance/CFO | - | 01/22/01 | |
Ivan M. Møller
COO | Chief Operating Officer | 52 | 01/18/01 |
David M. Kendall
CTO | Chief Tech/Sci/R&D Officer | 62 | 02/22/02 |
Director/Board Member | 57 | - | |
Anna Krassowska
IRC | Investor Relations Contact | - | - |
Ravinder Chahil
LAW | General Counsel | 56 | - |
Human Resources Officer | 39 | 01/20/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Leonard Kruimer
BRD | Director/Board Member | 66 | 04/19/04 |
Chairman | 69 | 01/15/01 | |
Kirsten Drejer
BRD | Director/Board Member | 68 | 19/18/19 |
Director/Board Member | 58 | 04/19/04 | |
Director/Board Member | 65 | 04/19/04 | |
Director/Board Member | 57 | - | |
Anneline Nansen
BRD | Director/Board Member | 55 | 01/21/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 62,626,184 | 62,198,687 ( 99.32 %) | 351,307 ( 0.5610 %) | 99.32 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
ZEALAND PHARMA A/S 0.60% | 373,134 | 0.60% | 34,729,969 $ |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |